Float Short %

18.61

Margin Of Safety %

Put/Call OI Ratio

0.02

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

0.82

Price

10.02

Target Price

26.89

Analyst Recom

Performance Q

7.85

Relative Volume

1.29

Beta

0.81

Ticker: KALV

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	KALV	8.74	0.21	0.00	484
2025-01-24	KALV	8.59	0.21	0.00	484
2025-01-27	KALV	8.79	0.21	0.00	489
2025-01-28	KALV	8.87	0.21	0.00	489
2025-01-29	KALV	8.78	0.21	0.00	489
2025-01-30	KALV	8.8	0.21	0.33	490
2025-01-31	KALV	8.94	0.21	0.33	495
2025-02-03	KALV	9.23	0.21	0.00	518
2025-02-04	KALV	9.76	0.21	0.14	527
2025-02-05	KALV	9.91	0.21	0.14	527
2025-02-06	KALV	9.63	0.20	0.00	586
2025-02-07	KALV	9.2	0.19	0.00	602
2025-02-10	KALV	9.19	0.19	0.00	602
2025-02-11	KALV	9.3	0.19	0.00	607
2025-02-12	KALV	9.32	0.19	0.00	611
2025-02-13	KALV	9.52	0.19	0.00	611
2025-02-14	KALV	9.78	0.19	0.00	617
2025-02-18	KALV	9.78	0.19	0.00	618
2025-02-19	KALV	10.7	0.18	0.00	632
2025-02-20	KALV	10.64	0.16	0.00	702
2025-02-21	KALV	10.02	0.02	0.01	6080
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	KALV	8.75	-4.3	-	-3.64
2025-01-24	KALV	8.59	-4.3	-	-3.64
2025-01-27	KALV	8.76	-4.3	-	-3.64
2025-01-28	KALV	8.87	-4.3	-	-3.64
2025-01-29	KALV	8.78	-4.3	-	-3.64
2025-01-30	KALV	8.77	-4.3	-	-3.64
2025-01-31	KALV	8.91	-4.3	-	-3.64
2025-02-03	KALV	9.22	-4.3	-	-3.62
2025-02-04	KALV	9.75	-3.3	-	-3.62
2025-02-05	KALV	9.91	-3.3	-	-3.62
2025-02-06	KALV	9.64	-3.3	-	-3.62
2025-02-07	KALV	9.22	-3.3	-	-3.62
2025-02-10	KALV	9.19	-3.3	-	-3.62
2025-02-11	KALV	9.27	-3.3	-	-3.62
2025-02-12	KALV	9.32	-3.3	-	-3.62
2025-02-13	KALV	9.53	-3.3	-	-3.62
2025-02-14	KALV	9.76	-3.3	-	-3.34
2025-02-18	KALV	9.77	-3.3	-	-3.34
2025-02-19	KALV	10.71	-3.3	-	-3.34
2025-02-20	KALV	10.64	-3.3	-	-3.34
2025-02-21	KALV	10.02	-3.3	-	-3.34
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	KALV	-0.56	5.60	21.35
2025-01-24	KALV	-0.56	5.60	21.35
2025-01-27	KALV	-0.56	5.83	21.35
2025-01-28	KALV	-0.56	5.83	21.75
2025-01-29	KALV	-0.56	5.83	21.75
2025-01-30	KALV	-0.56	5.83	21.75
2025-01-31	KALV	-0.56	5.83	21.75
2025-02-03	KALV	-0.56	5.77	21.75
2025-02-04	KALV	-0.08	5.77	21.75
2025-02-05	KALV	-0.08	5.77	21.75
2025-02-06	KALV	-0.08	5.77	21.75
2025-02-07	KALV	-0.08	5.77	21.80
2025-02-10	KALV	-0.08	3.35	21.80
2025-02-11	KALV	-0.08	3.35	21.80
2025-02-12	KALV	0.64	3.35	20.48
2025-02-13	KALV	0.64	3.35	20.48
2025-02-14	KALV	0.64	3.35	20.48
2025-02-18	KALV	1.77	2.00	19.80
2025-02-19	KALV	1.83	2.00	20.21
2025-02-20	KALV	1.75	2.00	20.21
2025-02-21	KALV	2.24	2.00	18.61
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.91

Avg. EPS Est. Current Quarter

-0.88

Avg. EPS Est. Next Quarter

-0.91

Insider Transactions

2.24

Institutional Transactions

Beta

0.81

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

77.7

Max Drawdown 5-Year %

-90.1

Target Price

26.89

P/E

Forward P/E

PEG

P/S

P/B

3.24

P/Free Cash Flow

EPS

-3.64

Average EPS Est. Cur. Y

-3.34

EPS Next Y. (Est.)

-2.52

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.29

Return on Equity vs Sector %

-135.9

Return on Equity vs Industry %

-120.3

EPS 1 7Days Diff

0.3

EPS 1 30Days Diff

0.3

EBIT Estimation

KalVista Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 150

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

stock quote shares KALV – KalVista Pharmaceuticals Inc Stock Price stock today

news today KALV – KalVista Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch KALV – KalVista Pharmaceuticals Inc yahoo finance google finance

stock history KALV – KalVista Pharmaceuticals Inc invest stock market

stock prices KALV premarket after hours

ticker KALV fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: KALV

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y